Relationships between age-related biochemical markers of bone turnover and OPG, TGF-β1 and TGF-β2 in native Chinese women

References

• Janssens K, ten Dijke P, Janssens S, Van HW. Transforming growth factor-beta 1 to the bone. Endocr Rev 2005;26:743–74
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2–12
   PubMed Web of Science ®Google Scholar
• Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610–5
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597–602
   PubMed Web of Science ®Google Scholar
• Mezquita-Raya P, de la Higuera M, García DF, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005;16:1368–74
   PubMed Web of Science ®Google Scholar
• Rogers A, Saleh G, Hannon RA, et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocinol Metab 2002;87:4470–75
   PubMed Web of Science ®Google Scholar
• Fuller K, Lean JM, Bayley KE, et al. A role for TGF-β1 in osteoclast differentiation and survival. J Cell Sci 2000;113:2445–53
   PubMed Web of Science ®Google Scholar
• Chenu C, Pfeilschifter J, Mundy GR, Roodman GD. Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci USA 1988;85:5683–7
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 2003;32:297–310
   Google Scholar
• Shaarawy M, Zaki S, Sheiba M, El-Minawi AM. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis. Clin Lab 2003;49:625–36
   PubMedGoogle Scholar
• Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337–49
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Z, Zhang H, et al. Susceptibility genes for osteoporotic fracture in postmenopausal Chinese women. J Bone Miner Res 2012;27:2582–91
   PubMed Web of Science ®Google Scholar
• Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008;19:1683–704
   PubMed Web of Science ®Google Scholar
• Eastell R, Ebeling PR. Bone turnover markers: a key tool for understanding osteoporosis. Osteoporos Int 2009;20:S237–8
   PubMed Web of Science ®Google Scholar
• Cohen FJ, Eckert S, Mitlak BH. Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women. Calcif Tissue Int 1998;63:277–82
   PubMed Web of Science ®Google Scholar
• Wu XY, Wu XP, Xie H, et al. Relationship between age-related reference values of serum osteoprotegerin and leptin in native Chinese women and compared with those in women of other races. Clin Chim Acta 2008;389:72–8
   PubMed Web of Science ®Google Scholar
• Ardawi MS, Maimani AA, Bahksh TA, et al. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study. Bone 2010;47:804–14
   Google Scholar
• Wu XY, Wu XP, Xie H, et al. Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women. Osteoporos Int 2010;21:275–85
   PubMed Web of Science ®Google Scholar
• Wu XY, Wu XP, Luo XH, et al. The relationship between the levels of gonadotropic hormones and OPG, leptin, TGF-beta1 and TGF-beta2 in Chinese adult women. Clin Chim Acta 2010;411:1296–305
   Google Scholar
• Karst M, Gorny G, Galvin RJ, Oursler MJ. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol 2004;200:99–106
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Hjorth P, Henriksen K, et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 2003;278:44975–87
   PubMed Web of Science ®Google Scholar
• Geiser AG, Zeng QQ, Sato M, et al. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. Bone 1998;23:87–93
   Google Scholar
• Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996;2:1132–6
   PubMed Web of Science ®Google Scholar
• Yanagisawa J, Yanagi Y, Masuhiro Y, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999;283:1317–21
   PubMed Web of Science ®Google Scholar
• Mori S, Fuku N, Chiba Y, et al. Cooperative effect of serum 25-hydroxyvitamin D concentration and a polymorphism of transforming growth factor-beta1 gene on the prevalence of vertebral fractures in postmenopausal osteoporosis. J Bone Miner Metab 2010;28:446–50
   PubMed Web of Science ®Google Scholar
• Toom A, Arend A, Gunnarsson D, et al. Bone formation zones in heterotopic ossifications: histologic findings and increased expression of bone morphogenetic protein 2 and transforming growth factors beta2 and beta3. Calcif Tissue Int 2007;80:259–67
   PubMed Web of Science ®Google Scholar
• Oh KW, Rhee EJ, Lee WY, et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol (Oxf) 2004;61:244–9
   Google Scholar
• Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005;16:417–23
   PubMed Web of Science ®Google Scholar
• Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003;115:291–7
   PubMed Web of Science ®Google Scholar
• Holecki M, Zahorska-Markiewicz B, Janowska J, et al. Osteoprotegerin – does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? Endokrynol Pol 2007;58:7–10
   Google Scholar
• Wiercinska-Drapalo A, Jaroszewicz J, Tarasow E, et al. Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. Prostaglandins Other Lipid Media 2005;78:160–8
   Google Scholar
• Lau HH, Ho AY, Luk KD, Kung AW. Transforming growth factor-beta1 gene polymorphisms and bone turnover, bone mineral density and fracture risk in southern Chinese women. Calcif Tissue Int 2004;74:516–21
   PubMedGoogle Scholar
• McGuigan FE, Macdonald HM, Bassiti A, et al. Large-scale population-based study shows no association between common polymorphisms of the TGFB1 gene and BMD in women. J Bone Miner Res 2007;22:195–202
   PubMedGoogle Scholar